Key result
Aptamer-based sensors enable real-time in vivo anthracycline monitoring for up to 7 days in rodents.
Why the study?
Anthracyclines carry a narrow therapeutic index and cardiotoxicity risk, but conventional therapeutic drug monitoring cannot resolve the sub-minute concentration dynamics that determine organ-specific drug exposure.
Do electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracycline chemotherapeutics compared to conventional sampling?
Do electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracycline chemotherapeutics compared to conventional sampling?
Electrochemical aptamer-based sensors provide high-resolution, real-time in vivo pharmacokinetic monitoring of anthracyclines in preclinical models, offering a potential future strategy to personalize dosing and minimize cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Enables real-time anthracycline TDM in patients; leaves open whether it improves dosing safety or outcomes.
Anthracycline agents, principally doxorubicin and daunorubicin, are widely used in oncology yet carry a narrow therapeutic index and pronounced interindividual pharmacokinetic variability that exposes patients simultaneously to the risk of subtherapeutic dosing and cumulative cardiotoxicity. Conventional therapeutic drug monitoring (TDM) based on periodic venous sampling and offline high-performance liquid chromatography cannot resolve the sub-minute concentration dynamics that determine organ-specific drug exposure. Electrochemical aptamer-based (EAB) sensors couple nucleic-acid aptamers, self-assembled monolayers, and methylene blue redox reporters on gold microelectrodes to convert binding-induced conformational changes into real-time, reagent-free electrochemical signals. Recent advances in this field fall into five areas: signal interrogation strategies, from kinetic differential measurement to calibration-free Fourier-transform impedance spectroscopy (FFT-EIS); interface engineering including nanostructured electrodes and AI-guided aptamer design; in vivo multi-compartment pharmacokinetic monitoring and closed-loop feedback drug delivery; the mechanisms of in vivo signal drift alongside antifouling countermeasures spanning hydrogel barriers, zwitterionic brushes, and xenonucleic acid backbone substitution; and FDA premarket pathways and clinical translation, including Premarket Approval requirements and the emerging Real-Time Clinical Trial (RTCT) framework. In live rodents, dual-compartment monitoring has resolved a reproducible 30–60 min plasma-to-ISF lag for doxorubicin at 12 s temporal resolution; calibration-free FFT-EIS interrogation achieves inter-animal coefficients of variation below 12% without individual pre-calibration; and xenonucleic acid backbone substitution has extended continuous in vivo operation to seven consecutive days. Unlike prior EAB reviews that survey general molecular targets or benchtop aptasensors, this review uniquely integrates anthracycline-specific in vivo pharmacokinetics, multi-compartment plasma–ISF monitoring, calibration-free interrogation, XNA-enabled long-term stability, and FDA/RTCT regulatory translation into a single clinical roadmap. Three gaps still separate rodent proof-of-concept work from chemotherapy patients: clinical-context validation, tumor microenvironment calibration, and anthracycline-specific XNA aptamer design.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a review in Oncology (Anthracycline chemotherapy). Electrochemical aptamer-based (EAB) sensors vs. Conventional therapeutic drug monitoring was evaluated. Electrochemical aptamer-based sensors enable real-time in vivo pharmacokinetic monitoring of anthracyclines, resolving a 30-60 min plasma-to-ISF lag at 12 s resolution in rodent models.
Synapse has enriched 10 related papers. Consider them for comparative context: